Latest Boston Scientific Corporation Stories
World's First 32-contact SCS Surgical Leads Designed to Provide More Focused Pain Relief for Patients with Chronic Pain MARLBOROUGH, Mass., Oct.
First Patient Enrolled in PLATINUM Diversity Trial Evaluating Performance in Women, Black Americans, Latinos/Hispanics, Native Americans and Alaska Natives with Coronary Artery Disease
Comprehensive Clinical Data from Randomized Trials Reviewed MARLBOROUGH, Mass., Oct.
MARLBOROUGH, Mass., Oct.
Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval MARLBOROUGH, Mass., Sept.
Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life MARLBOROUGH, Mass., Sept.
No Cases of Moderate or Severe Paravalvular Aortic Regurgitation at One Year MARLBOROUGH, Mass., Sept.
Data Will Focus on Areas of Significant Unmet Patient Need, Including Coronary Artery Disease and Aortic Valve Disease MARLBOROUGH, Mass., Sept.
MARLBOROUGH, Mass., Sept.
MARLBOROUGH, Mass., Sept. 2, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer AG.
- One who brings meat to the table; hence, in some countries, the official title of the grand master or steward of the king's or a nobleman's household.